{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=crizanlizumab",
    "query": {
      "intervention": "crizanlizumab"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=crizanlizumab&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T01:37:55.103Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03814746",
      "title": "Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease (SCD)"
      ],
      "interventions": [
        {
          "name": "Crizanlizumab (SEG101)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "12 Years to 100 Years"
      },
      "enrollment_count": 254,
      "start_date": "2019-07-26",
      "completion_date": "2026-11-05",
      "has_results": true,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-09-25T01:37:55.103Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Charlotte, North Carolina + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03814746"
    },
    {
      "nct_id": "NCT04611880",
      "title": "Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy"
      ],
      "interventions": [
        {
          "name": "Crizanlizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "25 Years to 75 Years"
      },
      "enrollment_count": 18,
      "start_date": "2021-01-25",
      "completion_date": "2025-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-09-25T01:37:55.103Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04611880"
    },
    {
      "nct_id": "NCT04505774",
      "title": "Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "theraputic heparin",
          "type": "DRUG"
        },
        {
          "name": "prophylactic heparin",
          "type": "DRUG"
        },
        {
          "name": "P2Y12",
          "type": "DRUG"
        },
        {
          "name": "Crizanlizumab Injection",
          "type": "DRUG"
        },
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Matthew Neal MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3591,
      "start_date": "2020-09-04",
      "completion_date": "2024-01-26",
      "has_results": true,
      "last_update_posted_date": "2024-12-30",
      "last_synced_at": "2026-09-25T01:37:55.103Z",
      "location_count": 81,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fontana",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04505774"
    },
    {
      "nct_id": "NCT04657822",
      "title": "Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Crizanlizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "6 Months to 100 Years"
      },
      "enrollment_count": 130,
      "start_date": "2021-06-10",
      "completion_date": "2031-06-10",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-09-25T01:37:55.103Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Augusta, Georgia + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04657822"
    },
    {
      "nct_id": "NCT04435184",
      "title": "Crizanlizumab for Treating COVID-19 Vasculopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Crizanlizumab",
          "type": "DRUG"
        },
        {
          "name": "0.9% saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2020-07-09",
      "completion_date": "2021-01-04",
      "has_results": true,
      "last_update_posted_date": "2021-11-09",
      "last_synced_at": "2026-09-25T01:37:55.103Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04435184"
    },
    {
      "nct_id": "NCT05833022",
      "title": "Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 297,
      "start_date": "2021-07-30",
      "completion_date": "2022-04-18",
      "has_results": false,
      "last_update_posted_date": "2023-04-27",
      "last_synced_at": "2026-09-25T01:37:55.103Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Wilmington, Delaware • St. Petersburg, Florida + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05833022"
    },
    {
      "nct_id": "NCT05334576",
      "title": "Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Crizanlizumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Andria Ford",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2022-08-01",
      "completion_date": "2025-07-01",
      "has_results": false,
      "last_update_posted_date": "2023-03-06",
      "last_synced_at": "2026-09-25T01:37:55.103Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05334576"
    },
    {
      "nct_id": "NCT03938454",
      "title": "A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Priapism"
      ],
      "interventions": [
        {
          "name": "Crizanlizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "100 Years",
        "sex": "MALE",
        "summary": "12 Years to 100 Years · Male only"
      },
      "enrollment_count": 36,
      "start_date": "2019-10-16",
      "completion_date": "2023-11-29",
      "has_results": true,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-09-25T01:37:55.103Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Farmington, Connecticut • Washington D.C., District of Columbia + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03938454"
    },
    {
      "nct_id": "NCT04053764",
      "title": "Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease (SCD)"
      ],
      "interventions": [
        {
          "name": "Crizanlizuamb",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2019-12-10",
      "completion_date": "2023-03-20",
      "has_results": true,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-09-25T01:37:55.103Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois • Baton Rouge, Louisiana + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04053764"
    },
    {
      "nct_id": "NCT03264989",
      "title": "Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease (SCD)"
      ],
      "interventions": [
        {
          "name": "crizanlizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "16 Years to 70 Years"
      },
      "enrollment_count": 57,
      "start_date": "2017-12-19",
      "completion_date": "2023-06-26",
      "has_results": true,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-09-25T01:37:55.103Z",
      "location_count": 12,
      "location_summary": "Orange, Florida • Tampa, Florida • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Orange",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03264989"
    }
  ]
}